Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee

American Journal of Gastroenterology

Volumn 99, Issue 7, 2004, Pages 1371-1385

  Kornbluth, Asher ^a,b   Sachar, David B ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; LIBRARY; MEDICAL EDUCATION; MEDLINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; ADULT; ARTICLE; COLORECTAL TUMOR; HUMAN; ILEITIS;

ADULT; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; HUMANS; POUCHITIS;

EID: 3843109109     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.40036.x     Document Type: Review

References (218)

1. Kornbluth A, Salomon P, Sacks HS, et al. Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J Clin Gastroenterol 1993;16:215-8.
2. Meyers S, Janowitz HD. The "natural history" of ulcerative colitis. An analysis of the placebo response. Am J Gastroenterol 1989;11:33-7.
3. Loftus EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmstead county, Minnesota, 1940-1993: Incidence, prevalence and survival. Gut 2000;46:336-43.
4. American Gastroenterology Association. The burden of gastrointestinal disease. Chapter 4. Intestinal diseases. 2001:30-5.
5. Tremaine WJ, Sandborn WJ, Loftus EV, et al. A prospective cohort study of practice guidelines for inflammatory bowel disease. Am J Gastroenterol 2001:2401-6.
6. Chutkan RK, Waye JD. Endoscopy in inflammatory bowel disease. In: Kirsner JD, ed. Inflammatory bowel disease. Philadelphia: WB. Saunders Company, 2000:453-79.
7. D'Haens G, Geboes K, Peelers M, et al. Patchy cecal inflammation associated with distal ulcerative colitis: A prospective endoscopic study. Am J Gastroenterol 1997;92:1275-9.
8. Jenkins D, Balsitis M, Gallivan S, et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol 1997;50:93-105.
9. Surawicz SM, Belie L. Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. Gastroenterology 1984;86:104-13.
10. Nostrant TT, Kumar NB, Appelman HD. Histopathology differentiates self-limited colitis from ulcerative colitis. Gastroenterology 1987;92:318-28.
11. Dundas SAC, Dutton J, Skipworth P. Reliability of rectal biopsy in distinguishing between chronic inflammatory bowel disease and acute self-limiting colitis. Histopathology 1997;31:60-6.
12. Surawicz CM. Differential diagnosis of colitis. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease. From bench to bedside. Baltimore: Williams and Wilkins, 1994:409-28.
13. Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996;110:1810-9.
14. Sandborn WJ, Loftus EV, Colombel JF, et al. Evaluation of serologic disease markers in a population-based cohort of patients with inflammatory bowel disease. Inflamm Bowel Dis 2001;7:192-201.
15. Legnani P, Kornbluth A. Difficult differential diagnoses in IBD: Ileitis and indeterminate colitis. Semin Gastrointest Dis 2001;12:211-22.
16. Truelove SC, Wilts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955;2:1041-5.
17. Hanauer S. Inflammatory bowel disease. N Engl J Med 1996;334:841-8.
18. Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis an overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263-76.
19. Sutherland LR, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis (Cochran Review). In: The Cochran Library, Issue 3. Oxford: Update Software, 2001.
20. Stein RB, Hanauer SB. Medical therapy for inflammatory Disease. Gastroenterol Clin North Am 1999;28:297-321.
21. Baron JH, Connell JE, Lennard-Jones J, et al. Sulfasalazine and salicylazophadimidine in ulcerative colitis. Lancet 1962;1:1094-6.
22. Dick AP, Grayson MJ, Carpenter RG, et al. Controlled trial of sulfasalazine in the treatment of ulcerative colitis. Gut 1964;5:437-42.
23. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multi-center study. Ann Int Med 1991;115:350-5.
24. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic therapy for mildly to moderately ulcerative colitis. A randomized trial. N Engl J Med 1987;317:1625-9.
25. Green JR, Lobo AJ, Holdworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of ulcerative colitis. Gastroenterology 1998;114:15-22.
26. Levine DS, Riff DS, Pruitt R, et al. A randomized, double-blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g) and meslamine (2.4 g) in the treatment of active, mild to moderate ulcerative colitis. Am J Gastroenterol 2002;97:1398-407.
27. Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild to moderate ulcerative colitis. Am J Gastroenterol 2002;97:473-9.
28. Zinberg J, Molinas S, Das KM. Double-blind, placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol 1990;85:562-6.
29. Feurle GE, Theuer D, Velasco S, et al. Olsalazine versus placebo in the treatment of mild-moderate ulcerative colitis: A randomized double-blind trial. Gut 1989;30:1354-61.
30. Rao SS, Dundas SA, Holdsworth CD, et al. Olsalazine or sulfasalazine in first attacks of ulcerative colitis? A double-blind study. Gut 1989;30:675-9.
31. Meyers S, Sachar DB, Present DH, et al. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology 1987;93:2255-62.
32. Hanauer SB, Kane S. The pharmacology of anti-inflammatory drugs in inflammatory bowel disease. In:Kirsner S, ed. Inflammatory bowel disease, Philadelphia: Saunders Publishing, 2000;510-28.
33. Rao SS, Can PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant to sulfasalazine. Scand J Gastroenterol 1987;22:322-7.
34. Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulfasalazine. Aliment Pharmacol Ther 1992;6:51-61.
35. Green JRB, Mansfield JC, Gibson A, et al. A double blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002;16:61-8.
36. Campieri M, Defranchis R, Bianchi G, et al. Mesalazine (5-ASA) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. Scand J Gastroenterol 1990;25:663-8.
37. D'Arienzo A, Panarese A, D'Armiento FP, et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: A double-blind placebo controlled clinical trial. Am J Gastroenterol 1990;85:1079-82.
38. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enemas in the treatment of distal ulcerative colitis, proctosigmoiditis and proctitis. Gastroenterology 1987;92:1894-8.
39. Hanauer SB, US Pentasa enema study group. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: Results of a multicenter placebo-controlled trial. Inflamm Bowel Dis 1998;4:79-83.
40. Sutherland LR, Martin F. 5-Aminosalicylic acid enemas in the maintenance of remission in distal ulcerative colitis and proctitis. Am J Gastroenterol 1987;1:3-6.
41. D'Albasio G, Trallou CO, Ghetti A, et al. Intermittent therapy with high dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Dis Colon Rectum 1990;33:394-7.
42. Marshall JK, Irvine EJ. Rectal aminosalicylate (ASA) therapy for distal ulcerative colitis: A meta-analysis. Aliment Pharmacol Ther 1995;9:293-300.
43. Biddle WL, Greenberger NJ, Swan JT, et al. 5-Aminosalicylic acid enemas. Effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988;94:1075-9.
44. Sutherland LR. Topical treatment of ulcerative colitis. Med Clin North Am 1990;74:119-31.
45. Watkinson G. Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate. Br Med J 1958;2:1077-82.
46. Truelove SC. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium: A report on a controlled therapeutic trial. Br Med J 1958;2:1072-7.
47. Campieri M, Lanfranchi GA, Bazzochi G, et al. Treatment of ulcerative colitis with high-dose 5-ASA enemas. Lancet 1981;2:270-3.
48. Danish 5-ASA study group. Topical 5-ASA vs. prednisolone in ulcerative proctosigmoiditis. Dig Dis Sci 1982;32:598-604.
49. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: A meta analysis. Gut 1997;40:775-80.
50. Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study. Gastroenterology 1998;115:525-32.
51. Danish Budesonide Study Group. Budesonide in distal colitis. Scand J Gastroenterol 1991;26:1225-9.
52. Lofberg R, Danielsson A, Suhr O, et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996;110:1713-8.
53. Farthing JJ, Rutland JD, Clar JL. Retrograde spread of hydrocortisone-containing foam given intrarectally in ulcerative colitis. Br Med J 1979;2:1822-7.
54. Jay M. Retrograde spreading of hydrocortisone enema in inflammatory bowel disease. Dig Dis Sci 1986;31:139-44.
55. Chapman NJ. Distribution of mesalamine enemas in patients with active distal ulcerative colitis. Mayo Clin Proc 1992;67:245-8.
56. Williams CN, Haber G, Aquino JA. Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spreading using TC-labeled 5-ASA suppositories. Dig Dis Sci 1987;32:715-55.
57. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92:1867-71.
58. Hanauer S, Good LI, Goodman MW, et al. Long term use of mesalazine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000;95:1749-54.
59. D'Albasio G, Paoluzi P, Campieri M, et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: A double-blind placebo-controlled trial. Am J Gastroenterol 1998;93:799-803.
60. Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001;49:783-9.
61. Green JRB, Gibson JA, Kerr GD, et al. Maintenance of remission of ulcerative colitis: A comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. Aliment Pharmacol Ther 1998;12:1207-16.
62. D'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: A randomized double-blind study. Am J Gastroenterol 1992;1997:1143-7.
63. Lindgren S, Suhr O, Persson T, et al. Treatment of active distal ulcerative colitis and maintenance of remission with Entercort enema: A randomized controlled dosage study. Gut 1997;41:A223.
64. Hanauer SB, Schwartz J, Robinson M, et al. Mesalamine capsules (Pentasa) for treatment of active ulcerative colitis: Results of a controlled trial. Am J Gastroenterol 1993;88:1188-97.
65. Willoughby CP, Cowan RE, Gould SR. Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scand J Gastroenterol Suppl 1988;148:40-4.
66. Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997;126:364-71.
67. Pullan RD, Rhodes J, Ganesh S. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994;330:811-5.
68. Sandborn WJ. Nicotine therapy for ulcerative colitis: A review of rationale, mechanisms, pharmacology, and clinical results. Am J Gastroenterol 1999;94:1161-71.
69. Thomas GAO, Rhodes J, Mani V, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995;332:988-92.
70. Truelove SC, Wilts IJ. Cortisone in ulcerative colitis: Report on a therapeutic trial. Br Med J 2:1041-9.
71. Lennard-Jones JE. An assessment of prednisone, salazopyrine and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut 1960;1:217-22.
72. Baron JH. Outpatient treatment of ulcerative colitis. Br Med J 1962;2:441-4.
73. Meyers S. Oral and parenteral corticoids. In: Peppercorn M, ed. Therapy of inflammatory bowel disease. New medical and surgical approaches. New York: Marcel Decker, Inc., 1990:1-34.
74. NIH Consensus Development Panel. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. JAMA 2001;285:785-95.
75. Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol 1999;94:878-83.
76. Bernstein CN. Neoplastic and other complications of inflammatory bowel disease. Curr Gastroenterol Rep 2000;2:451-9.
77. Bernstein C, Katz S. Guidelines for ostorporosis and inflammatory bowel disease. A guide to diagnosis and management for the gastroenterologist (monograph). The American College of Gastroenterology, 2003.
78. American Gastroenterological Association. American Gastroenterological Association position statement: Guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003;124:791-4.
79. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
80. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 1999;42:2309-18.
81. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
82. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 1982;284:1291-2.
83. Rosenberg JL, Wall AJ, Settles RH, et al. A controlled trial of azathioprine in the treatment of chronic ulcerative colitis. Gastroenterology 1973;64:793-801.
84. Liang LC, Rubin PH, Bodian G, et al. 6-Mercaptopurine is an effective steroid-sparing agent in the treatment of refractory ulcerative colitis (abstract). Gastroenterology 1992;102:A653.
85. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990;85:717-22.
86. Lobo AJ, Foster PN, Burke D, et al. The role of azathioprine in the management of ulcerative colitis. Dis Col Rectum 1990;33:374-7.
87. Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001;48:591-2.
88. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: Short and long term toxicity. Ann Intern Med 1989;111:641-9.
89. Fraser AG, Jewell DP. Side effects of azathioprine given for inflammatory bowel disease-A 30 year audit. Gastroenterology 2000;118:A787.
90. Connell WR, Kamm MA, Dickson M, et al. Long term neoplasia risk after azathioprine treatment with inflammatory bowel disease. Lancet 1994;343:1249-52.
91. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
92. Cuffari C, Hunt S, Bayless T. Utilization of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-6.
93. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;49:665-70.
94. Gupta P, Gokhale R, Kirschner BS. 6-Mercaptopurine metabolite levels in children with IBD. J Pediatr Gastroenterol Nutr 2001;33:450-4.
95. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;12:904-15.
96. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
97. Colombel JF, Ferrari N, Debuyserre H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosupression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
98. Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992;305:20-2.
99. George J, Present DH, Pou R, et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996;91:1711-4.
100. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine of inflammatory bowel disease: A 30 year review. Gut 2002;50:485-9.
101. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: A double-blind, randomized Israeli multicenter trial. Gastroenterology 1996;110:1416-21.
102. Misiewicz JJ, Lennard-Jones JE, Connell AM, et al. Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;1:185-8.
103. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulfasalazine (Salazopyrin). Gut 1973;14:923-6.
104. Azad Khan AK, Howes DT, Piris J, et al. Optimum dose of sulfasalazine for maintenance treatment in ulcerative colitis. Gut 1980;21:232-40.
105. Sandberg-Gertzen H, Jarnerot G, Draaz W. Azodisal sodium in the treatment of ulcerative colitis: A study of tolerance and relapse-prevention properties. Gastroenterology 1986;90:1024-30.
106. Ireland A, Jewell DP. Olsalazine in patients intolerant of SASP. Scand J Gastroenterol 1989;22:1038-40.
107. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed release 5-aminosalicylic acid, (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gut 1988;29:669-74.
108. Dew MJ, Hughes P, Harries AD, et al. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J 1982;285:1012-4.
109. Dew MJ, Harries AD, Evans N, et al. Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. Br Med J 1983;287:413-5.
110. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988;94:1383-9.
111. Mulder CJJ, Tytgat GN, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988;95:1449-53.
112. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulfasalazine for main-taining remission of ulcerative colitis. Aliment Pharmacol Ther 1989;3:183-91.
113. Bianchi Porro G, Ardizzone S, Fasoli R, et al. Comparison of mesalazine with sulfasalazine in prophylactic treatment of ulcerative colitis (abstract). Gut 1989;30:A1467.
114. Gionchetti P, Campieri M, Beluzzi A, et al. Pentasa in maintenance treatment of ulcerative colitis (letter). Gastroenterology 1990;98:251-5.
115. Hanauer S, for the Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann Intern Med 1996;124:204-11.
116. Green JRB, Mansfield JC, Gibson JA, et al. A double-blind comparison of balsalazide, 6.75 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002;16:61-8.
117. Sachar DB. Maintenance therapy in ulcerative colitis and Crohn's disease. J Clin Gastroenterol 1995;20:117-22.
118. Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 1995;40:296-304.
119. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis. Gut 1988;29:835-7.
120. Killerich S, Ladefoged K, Rennem T, et al. Prophylactic effects of olsalazine v sulfasalazine during 12 months of maintenance treatment of ulcerative colitis. Gut 1992;33:252-5.
121. Rijk MCM, Van Lier HJJ, van Tongeren JHM. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: A prospective, double-blind, randomized multicenter trial. Am J Gastroenterol 1992;87:438-42.
122. McIntyre P, Rodriges CA, Lennard-Jones JE, et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis: A double-blind comparison with sulfasalazine. Aliment Pharmacol Ther 1988;2:237-43.
123. Rutgeerts P, International Study Group. Comparative efficacy of coated, oral 5-aminosalicylic acid (claversal) and sulfasalazine for maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1989;3:183-91.
124. Travis SPL, Tysk C, Jarnerot G, et al. A dose-ranging study of olsalazine in ulcerative colitis. Gut 1992;33:546-9.
125. Giaffer H, Holdsworth CD, Lennard-Jones JE, et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4G/day compared to 2G/day. Aliment Pharamcol Ther 1992;6:479-85.
126. Fockens P, Mulder CJJ, Tytgat GNJ, et al. and the Dutch Pentasa Study Group. Comparison of safety and efficacy of 1.5 vs. 3.0 gram oral slow-release mesalamine (Pentasa) in the maintenance treatment of ulcerative colitis. Eur J Gastroenterol Hepatol 1995;11:1025-30.
127. Hanauer S, Powers B, Robinson M, et al. Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo (abstract). Gastroenterology 1994;106:A696.
128. Kruis W, Judmaier G, Kayasseh L, et al. Double-blind dose-finding study of olsalazine vs sulfasalazine for maintenance therapy of ulcerative colitis (abstract). Eur J Gastroenterol Hepatol 1995;7:391-6.
129. Green JRB, Swan CHJ, Rowlinson A, et al. Comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992;6:647-52.
130. Truelove SC, Jewell D. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067-70.
131. Truelove SC, Willoughby CP, Lee G, et al. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978;2:1086-8.
132. Jarnerot G, Rolny P, Saulbergh-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-13.
133. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in ulcerative colitis. Gut 1986;27:1210-2.
134. Meyers S, Sachar DB, Goldberg JD, et al. Corticotropin vs hydrocortisone in the intravenous treatment of ulcerative colitis. Gastroenterology 1983;85:351-7.
135. Kaplan HP, Portnoy B, Binder HJ, et al. A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis. Gastroenterology 1975;69:91-5.
136. Powell-Tuck J, Bucknell NA, Lennard-Jones JE. A controlled comparison of corticotropin and hydrocortisone in the treatment of severe proctocolitis. Scand J Gastroenterol 1977;12:971-5.
137. Rosenberg W, Ireland A, Jewell D. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 1990;12:40-1.
138. Dickinson RJ, O'Connor HJ, Pinder I, et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985;26:1380-4.
139. Mantzaris GJ, Petraki K, Archavlis E, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute severe ulcerative colitis. Scand J Gastroenterol 2001;36:971-4.
140. Dickinson RJ, Ashton MG, Axon ATR, et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980;79:1199-2004.
141. McIntyre DB, Powell-Tuck J, Wood SR. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986;27:481-5.
142. Roediger WE. The starved colon-diminished mucosal nutrition, diminished absorption and colitis. Dis Colon Rectum 1990;33:858-62.
143. Koretz RL, Lipman TO, Klein S. AGA technical review on parenteral nutrition. Gastroenterology 2001;121:970-1001.
144. Kornbluth A, Marion J, Bharuca S, et al. The treatment of severe ulcerative and Crohn's colitis. A critical analysis of the defined trials. J Clin Gastroenterol 1995;18:242-6.
145. Cottone M, Pietrosi G, Martarana G, et al. Prevalence of CMV infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001;96:773-5.
146. Papadakis KA, Tung JK, Binder SW, et al. Outcome of CMV infections in patients with inflammatory bowel disease. Am J Gastroenterol 2000;96:2137-42.
147. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
148. Van Assche G, D'Haens G, Noman M, et al. Randomized double-blind comparison of 4 mg/kg versus 2 mg/kg IV cyclosporine in severe ulcerative colitis. Gastroenterology 2002;122:A668.
149. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporine in ulcerative colitis: A 5-year experience. Am J Gastroenterol 1999;94:1587-92.
150. Yoon C, Kornbluth A, George J, et al. Is cyclosporine as effective in chronic ulcerative colitis as in severe ulcerative colitis. Gastroenterology 1998;114:G4586.
151. Andreoli A, Falasco G, Mangiaropti R, et al. Efficacy of long-term oral 6-mercaptopurine therapy in maintaining remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Gastroenterology 1999;116:G2883.
152. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-9.
153. Sternthal M, George J, Kornbluth A, et al. Toxicity associated with the use of cyclosporin in patients with inflammatory bowel disease (abstract). Gastroenterology 1996:A1019.
154. Hyde GM, Jewell DP, Kettlewell MG, et al. Cyclosporine for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001;44:1436-40.
155. Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: Postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003;125:320-7.
156. Present DH, Wolfson D, Gelernt IM, et al. Medical decompression of toxic megacolon by "rolling". J Clin Gastroenterol 1988;10:485-90.
157. Truelove SC, Mark CG. Toxic megacolon. Clin Gastroenterol 1981;10:107-17.
158. Korelitz BI, Dyck WP, Klion FM. Fate of the rectum and distal colon after subtotal colectomy for ulcerative colitis. Gut 1969;10:198-201.
159. Robert JH, Sachar DB, Aufses AH, et al. Management of severe hemorrhage in ulcerative colitis. Am J Surg 1990;159:550-5.
160. Greenstein AJ, Sachar DB, Gorbas A, et al. Outcome of toxic dilation in ulcerative and Crohn's colitis. J Clin Gastroenterol 1985;7:137-44.
161. Hanauer SB. How do I treat erythema nodosum, aphthous ulcerations and pyoderma gangrenosum? Inflamm Bowel Dis 1998;4:70.
162. Talansky A, Meyers S, Greenstein AJ, et al. Does intestinal resection heal the pyoderma of inflammatory bowel disease? J Clin Gastroenterol 1983;5:207-10.
163. Altman AR, Maltz CR, Janowitz HD. Autoimmune hemolytic anemia in ulcerative colitis. Dig Dis Sci 1979;24:282-5.
164. Arner O. Autoimmune hemolytic anemia in ulcerative colitis cured by colectomy. Acta Med Scand 1971;189:275-8.
165. Cangemi JR, Wiesner RH, Beaver SJ, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 1989;96:790-4.
166. Mahadevan U, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology 2003;124:1638-50.
167. Sandborn WJ, Tremaine WJ, Batts KP, et al. Pouchitis following ileal pouch-anal anastomosis: A pouchitis disease activity index. Mayo Clin Proc 1994;69:409-15.
168. Shen B, Achkar JP, Lashner B, et al. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 2001;121:261-7.
169. Shen B, Shermock KB, Fazio VW, et al. A cost-effectiveness analyis of diagnostic strategies for symptomatic patients with ileal pouch-anal anastamosis. Am J Gastroenterol 2003;98:2460-7.
170. Hurst RD, Molinari M, Chung TP, et al. Prospective study of incidence, timing, and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996;131:497-502.
171. Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996;38:234-9.
172. Subramani K, Harpaz N, Billotta J, et al. Refractory pouchitis: Does it reflect underlying Crohn's disease? Gut 1993;34:1539-42.
173. Shen B, Achkar JP, Lashner BA, et al. Irritable pouch syndrome: A new category of diagnosis for symptomatic patients with ileal pouch-anal anastamosis. Am J Gastroenterol 2002;97:972-7.
174. Sandborn W, McLeod R, Jewell D. Pharmacotherapy for inducing and maintaining remission in pouchitis (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software, 2000.
175. Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301-5.
176. Sambuelli A, Boerr L, Negreira S, et al. Budesonide enema in pouchitis-A double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther 2002;16:27-34.
177. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994;39:1193-6.
178. Scott AD, Phillips RKS. Ileitis and pouchitis after colectomy for ulcerative colitis. Br J Surg 1989;76:668-9.
179. Gionchetti P, Rizello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A randomized placebo-controlled, double-blind trial. Gastroenterology 2000;119:305-9.
180. Gionchetti P, Rizello F, Venturi A, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind placebo controlled trial. Gastroenterology 2003:124.
181. Greenstein AJ, Sachar DB, Smith H, et al. Cancer in ulcerative and left-sided ulcerative colitis. Factors determining risk. Gastroenterology 1979;77:290-4.
182. Sugita A, Sachar DB, Bodian C, et al. Colorectal cancer in ulcerative colitis: Influence of anatomical extent and age at onset on colitis-cancer interval. Gut 1991;32:167-9.
183. Gilat T, Fireman Z, Grossman A, et al. Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. Gastroenterology 1988;94:870-7.
184. Sachar DB. Cancer risk in inflammatory bowel disease: Myths and metaphors. In: Riddel RH, ed. Dysplasia and cancer in colitis. New York: Elsevier, 1991:5-9.
185. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001;48:526-35.
186. Greenstein AJ, Sachar DB, Pucillo A, et al. Cancer in universal and left-sided ulcerative colitis. Clinical and pathological features. Mt Sinai J Med 1979;46:25-32.
187. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis. A cohort study of primary referrals from three centers. Gut 1988;29:206-17.
188. Shetty K, Rybicki L, Brzezinski A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999;94:1643-9.
189. Broome U, Lofberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. Hepatology 1995;22:1404-8.
190. Nuako KW, Ahlquist DA, Sandborn WJ, et al. Primary sclerosing cholangitis
191. Loftus E, Sandborn WJ, Tremaine WJ, et al. Cumulative risk factors associated with colorectal neoplasia in 184 patients with primary sclerosing cholangitis with and without ulcerative colitis. Gastroenterology 1996;110:432-40.
192. Pardi DS, Loftus EV, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-93.
193. Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor on colorectal cancer in IBD. Gastroenterology 2001;120:1356-62.
194. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention: A case control study. Aliment Pharmacol Ther 2000;14:145-53.
195. Ullman T, Croog V, Harpaz N, et al. Preventing neoplasia progression in ulcerative colitis: Role of mesalamine (abstract).Gastroenterology 124:A242,2003.
196. Pinczowski D, Ekbom A, Baron Y, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study. Gastroenterology 1994;107:117-20.
197. Moody GA, Jayanthi V, Probert CS, et al. Long term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis. Eur J Gastroenterol Hepatol 1996;8:1179-83.
198. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9.
199. Greenstein AJ, Slater G, Heimann TM, et al. Comparison of multiple synchronous colorectal cancers in ulcerative colitis, familial polyposis coli, and de novo cancer. Ann Surg 1986;203:123-8.
200. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994;107:934-44.
201. Vemulapalli R, Lance P. Cancer surveillance in ulcerative colitis: More of the same or progress? Gastroenterology 1994;107:1196-9.
202. Bernstein CN. Cancer surveillance in inflammatory bowel disease. Curr Gastroenterol Rep 1999:496-504.
203. Lashner BA, Silverstein MD, Hanauer SB. Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program. Dig Dis Sci 1989;10:1536-41.
204. Eaden JA, Abrams K, Mayberry JS. The risk of colorectal cancer in ulcerative colitis: A meta analysis. Gut 2001;48:526-35.
205. Melville DM, Jass JR, Morson BC, et al. Observer study of the grading of dysplasia in ulcerative colitis: Comparison with clinical outcome. Hum Pathol 1989;20:1008-14.
206. Rosenstock E, Farmer RG, Petras R, et al. Surveillance for colorectal cancer in ulcerative colitis. Gastroenterology 1985;89:1342.
207. Nugent FW, Haggit RC, Gilpin PA. Cancer surveillance in ulcerative colitis. Gastroenterology 1991;100:1241-8.
208. Blackstone M, Riddell RW, Rogers BHG, et al. Dysplasia associated lesion or mass (DALM) detected by colonoscopy in longstanding ulcerative colitis: An indication for colectomy. Gastroenterology 1981;80:366-74.
209. Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut 1992;33:938-41.
210. Reiser JR, Waye JD, Janowitz HD, et al. Adenocarcinoma in strictures of ulcerative colitis without antecedent dysplasia by colonoscopy. Am J Gastroenterol 1994;89:119-22.
211. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994;343:71-4.
212. Woolrich AJ, DaSilva MD, Korelitz BI. Surveillance in the routine management of ulcerative colitis: The predictive value of low grade dysplasia. Gastroenterology 1992;103:431-8.
213. Ullman TA, Loftus EV, Kakar S, et al. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 2002;97:922-7.
214. Ullman TA, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003;125:1311-9.
215. Bernstein CM. ALMs versus DALMs in ulcerative colitis: Polypectomy or colectomy? Gastroenterology 1999;117:1488-91.
216. Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: Conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999;117:1295-300.
217. Engelgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999;117:1288-94.
218. Niraj J, Kornbluth A, Croog V, et al. The fate of indefinite dysplasia in ulcerative colitis (abstract). Gastroenterology 2003;124:A649.